Modeling of Blood-Brain Barrier (BBB) Dysfunction and Immune Cell Migration Using Human BBB-on-a-Chip for Drug Discovery Research.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
12 Jun 2024
Historique:
received: 31 03 2024
revised: 03 06 2024
accepted: 05 06 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

Blood-brain barrier (BBB) dysfunction is a key feature in neuroimmunological and neurodegenerative diseases. In this study, we developed a microfluidic human BBB-on-a-chip to model barrier dysfunction and immune cell migration using immortalized TY10 brain endothelial cells, pericytes, and astrocytes. It was found that immortalized TY10 brain endothelial cells developed a microvascular structure under flow. Pericytes were localized on the basal side surrounding the TY10 microvascular structure, showing an in vivo-like structure. Barrier integrity increased under co-culture with pericytes. In addition, both ethylenediaminetetraacetic acid (EDTA) and anti-Claudin-5 (CLDN5) neutralizing antibody caused a decrease in the transendothelial electrical resistance (TEER). EDTA caused the leakage of 20 kDa dextran, suggesting different effects on the BBB based on the mechanism of action, whereas anti-CLDN5 antibody did not cause leakage. In the tri-culture model, human T cells migrated through endothelial vessels towards basal C-X-C motif chemokine ligand 12 (CXCL12). The live-imaging analysis confirmed the extravasation of fluorescence-labelled T cells in a CXCL12-concentration- and time-dependent manner. Our BBB model had an in vivo-like structure and successfully represented barrier dysfunction and transendothelial T cell migration. In addition, our study suggests that the inhibition of CLDN5 attenuates the BBB in humans. This platform has various potential uses in relation to the BBB in both drug discovery research and in elucidating the mechanisms of central nervous system diseases.

Identifiants

pubmed: 38928202
pii: ijms25126496
doi: 10.3390/ijms25126496
pii:
doi:

Substances chimiques

Claudin-5 0
Chemokine CXCL12 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Astellas Pharma (Japan)
ID : This work was funded by Astellas Pharma Inc.

Auteurs

Masato Ohbuchi (M)

Applied Research & Operations, Astellas Pharma Inc., Tsukuba 305-8585, Ibaraki, Japan.

Mayu Shibuta (M)

Applied Research & Operations, Astellas Pharma Inc., Tsukuba 305-8585, Ibaraki, Japan.

Kazuhiro Tetsuka (K)

Applied Research & Operations, Astellas Pharma Inc., Tsukuba 305-8585, Ibaraki, Japan.

Haruna Sasaki-Iwaoka (H)

Applied Research & Operations, Astellas Pharma Inc., Tsukuba 305-8585, Ibaraki, Japan.

Masayo Oishi (M)

Applied Research & Operations, Astellas Pharma Inc., Tsukuba 305-8585, Ibaraki, Japan.

Fumitaka Shimizu (F)

Department of Neurology and Clinical Neuroscience, Graduate School of Medicine, Yamaguchi University, Ube 755-8505, Yamaguchi, Japan.

Yasuhisa Nagasaka (Y)

Applied Research & Operations, Astellas Pharma Inc., Tsukuba 305-8585, Ibaraki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH